{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:04:36Z","timestamp":1761897876563},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Epidemiologische Untersuchungen zeigen, dass etwa 2\u20133\u202f% aller \u00d6sterreicher*innen einen Diabetes mellitus mit Nierenbeteiligung aufweisen. Dies betrifft somit in \u00d6sterreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der diabetischen Nierenerkrankung kann durch Lebensstilinterventionen und Optimierung des arteriellen Blutdrucks, Blutzuckers und spezielle Medikamentenklassen vermindert werden. In diesem gemeinsamen Artikel der \u00d6sterreichischen Gesellschaften f\u00fcr Nephrologie und Diabetologie werden die entsprechende Diagnostik und therapeutische Strategien bei diabetischer Nierenerkrankung vorgeschlagen.<\/jats:p>","DOI":"10.1007\/s00508-022-02147-3","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:03:25Z","timestamp":1682550205000},"page":"182-194","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetische Nierenerkrankung (Update 2023)","Diabetic kidney disease (update 2023)"],"prefix":"10.1007","volume":"135","author":[{"given":"Harald","family":"Sourij","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich C.","family":"Prischl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2147_CR1","volume-title":"\u00d6sterreichisches Dialyse- und Transplantationsregister","author":"\u00d6sterreichische Gesellschaft f\u00fcr Nephrologie.","year":"2022","unstructured":"\u00d6sterreichische Gesellschaft f\u00fcr Nephrologie. \u00d6sterreichisches Dialyse- und Transplantationsregister. Bd. 2022. 2022."},{"key":"2147_CR2","volume-title":"Austrian dialysis and transplant registry","author":"R Kramar","year":"2016","unstructured":"Kramar\u00a0R. Austrian dialysis and transplant registry. 2016."},{"key":"2147_CR3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ndt\/gfv113","volume":"30","author":"FC Prischl","year":"2015","unstructured":"Prischl\u00a0FC, et al. Diabetes-related end-stage renal disease in Austria 1965\u20132013. Nephrol Dial Transplant. 2015;30:1920\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"2147_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan\u00a0DM. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30\u00a0years: overview. Diabetes Care. 2014;37:9\u201316.","journal-title":"Diabetes Care"},{"key":"2147_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1681\/ASN.2013091004","volume":"25","author":"IH de Boer","year":"2014","unstructured":"de Boer\u00a0IH, et\u00a0al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J\u00a0Am Soc Nephrol. 2014;25:2342\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"2147_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253\u20139.","journal-title":"Lancet"},{"key":"2147_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner\u00a0BM, et\u00a0al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N\u00a0Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2147_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis\u00a0EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N\u00a0Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"2147_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving\u00a0HH, et\u00a0al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N\u00a0Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"2147_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12682","volume-title":"Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections. J\u00a0R Stat Socc Ser\u00a0A","author":"A Geroldinger","year":"2019","unstructured":"Geroldinger\u00a0A, Hronsky\u00a0HA, Endel\u00a0F, Endel\u00a0G, Oberbauer\u00a0R, Heinze\u00a0G. Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections. J\u00a0R Stat Socc Ser\u00a0A. 2019. https:\/\/doi.org\/10.1111\/rssa.12682."},{"key":"2147_CR11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.2215\/CJN.03700417","volume":"12","author":"LR Zelnick","year":"2017","unstructured":"Zelnick\u00a0LR, et\u00a0al. Diabetes and CKD in the United States Population, 2009\u20132014. Clin J Am Soc Nephrol. 2017;12:1984\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2147_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler\u00a0AI. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225\u201332.","journal-title":"Kidney Int"},{"key":"2147_CR13","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox\u00a0CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a\u00a0meta-analysis. Lancet. 2012;380:1662\u201373.","journal-title":"Lancet"},{"key":"2147_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ajcp\/38.3.270","volume":"38","author":"P Kimmelstiel","year":"1962","unstructured":"Kimmelstiel\u00a0P, Kim\u00a0OJ, Beres\u00a0J. Studies on renal biopsy specimens, with the aid of the electron microscope. I. Glomeruli in diabetes. Am J Clin Pathol. 1962;38:270\u20139.","journal-title":"Am J Clin Pathol"},{"key":"2147_CR15","first-page":"83","volume":"12","author":"P Kimmelstiel","year":"1936","unstructured":"Kimmelstiel\u00a0P, Wilson\u00a0C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12:83\u201398.7.","journal-title":"Am J Pathol"},{"issue":"Suppl 2","key":"2147_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diab.32.2.S64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen\u00a0CE, Christensen\u00a0CK, Vittinghus\u00a0E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64\u201378.","journal-title":"Diabetes"},{"key":"2147_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI111523","volume":"74","author":"SM Mauer","year":"1984","unstructured":"Mauer\u00a0SM, et al. Structural-functional relationships in diabetic nephropathy. J\u00a0Clin Invest. 1984;74:1143\u201355.","journal-title":"J Clin Invest"},{"issue":"Suppl 4","key":"2147_CR18","first-page":"958","volume":"5","author":"JM Steinke","year":"2008","unstructured":"Steinke\u00a0JM, Mauer\u00a0M, International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008;5(Suppl 4):958\u201363.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"Suppl 2","key":"2147_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00508-012-0262-6","volume":"124","author":"M Auinger","year":"2012","unstructured":"Auinger\u00a0M, et\u00a0al. Diabetic nephropathy\u2014Update 2012. Wien Klin Wochenschr. 2012;124(Suppl 2):42\u20139.","journal-title":"Wien Klin Wochenschr"},{"key":"2147_CR20","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","volume":"289","author":"HJ Kramer","year":"2003","unstructured":"Kramer\u00a0HJ, Nguyen\u00a0QD, Curhan\u00a0G, Hsu\u00a0CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273\u20137.","journal-title":"JAMA"},{"key":"2147_CR21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2337\/db05-1620","volume":"55","author":"R Retnakaran","year":"2006","unstructured":"Retnakaran\u00a0R, et\u00a0al. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes. 2006;55:1832\u20139.","journal-title":"Diabetes"},{"key":"2147_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2369-14-46","volume":"14","author":"A Rodriguez-Poncelas","year":"2013","unstructured":"Rodriguez-Poncelas\u00a0A, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2\u00a0study. BMC Nephrol. 2013;14:46.","journal-title":"BMC Nephrol"},{"key":"2147_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/dc08-2186","volume":"32","author":"MC Thomas","year":"2009","unstructured":"Thomas\u00a0MC, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32:1497\u2013502.","journal-title":"Diabetes Care"},{"key":"2147_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi\u00a0F, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419\u201330.","journal-title":"Lancet"},{"key":"2147_CR25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2337\/dc15-0184","volume":"38","author":"AS Krolewski","year":"2015","unstructured":"Krolewski\u00a0AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38:954\u201362.","journal-title":"Diabetes Care"},{"key":"2147_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2337\/dc21-1688","volume":"45","author":"HC Looker","year":"2022","unstructured":"Looker\u00a0HC, et al. Structural lesions on kidney biopsy in youth-onset and adult-onset type 2 diabetes. Diabetes Care. 2022;45:436\u201343.","journal-title":"Diabetes Care"},{"key":"2147_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert\u00a0TW, et\u00a0al. Pathologic classification of diabetic nephropathy. J\u00a0Am Soc Nephrol. 2010;21:556\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"2147_CR28","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","volume-title":"Diabetes management in chronic kidney disease: a consensus report by the","author":"IH de Boer","year":"2022","unstructured":"de Boer\u00a0IH, et\u00a0al. Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022. https:\/\/doi.org\/10.2337\/dci22-0027."},{"key":"2147_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey\u00a0AS, et\u00a0al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A\u00a0new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2147_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey\u00a0AS, et\u00a0al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766\u201372.","journal-title":"Clin Chem"},{"key":"2147_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac197","author":"EL Fu","year":"2022","unstructured":"Fu\u00a0EL, et al. Removing race from the CKD-EPI equation and its impact on prognosis in a\u00a0predominantly White European population. Nephrol Dial Transplant. 2022. https:\/\/doi.org\/10.1093\/ndt\/gfac197.","journal-title":"Nephrol Dial Transplant"},{"key":"2147_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey\u00a0AS, et\u00a0al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"2147_CR33","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/jama.2012.4623","volume":"307","author":"K Kalantar-Zadeh","year":"2012","unstructured":"Kalantar-Zadeh\u00a0K, Amin\u00a0AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307:1976\u20137.","journal-title":"JAMA"},{"key":"2147_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.ajkd.2009.12.011","volume":"55","author":"SL White","year":"2010","unstructured":"White\u00a0SL, Polkinghorne\u00a0KR, Atkins\u00a0RC, Chadban\u00a0SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis. 2010;55:660\u201370.","journal-title":"Am J Kidney Dis"},{"key":"2147_CR35","doi-asserted-by":"publisher","first-page":"g4507","DOI":"10.1136\/bmj.g4507","volume":"349","author":"S Carville","year":"2014","unstructured":"Carville\u00a0S, Wonderling\u00a0D, Stevens\u00a0P. Early identification and management of chronic kidney disease in adults: Summary of updated NICE guidance. BMJ. 2014;349:g4507.","journal-title":"BMJ"},{"key":"2147_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2337\/dc18-S010","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 10. Microvascular complications and foot care: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41:105\u2013S18.","journal-title":"Diabetes Care"},{"key":"2147_CR37","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1\u2013S115.","journal-title":"Kidney Int"},{"key":"2147_CR38","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/ajcn\/nqab417","volume":"115","author":"V Bellizzi","year":"2022","unstructured":"Bellizzi\u00a0V, et al. No additional benefit of prescribing a\u00a0very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a\u00a0pragmatic, randomized, controlled trial. Am J Clin Nutr. 2022;115:1404\u201317.","journal-title":"Am J Clin Nutr"},{"key":"2147_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13668-021-00383-z","volume":"11","author":"FP Cappuccio","year":"2022","unstructured":"Cappuccio\u00a0FP, et\u00a0al. Sodium and health: Old myths and a\u00a0controversy based on denial. Curr Nutr Rep. 2022;11:172\u201384.","journal-title":"Curr Nutr Rep"},{"key":"2147_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/dc10-1723","volume":"34","author":"EI Ekinci","year":"2011","unstructured":"Ekinci\u00a0EI, et\u00a0al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34:703\u20139.","journal-title":"Diabetes Care"},{"key":"2147_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc10-1722","volume":"34","author":"MC Thomas","year":"2011","unstructured":"Thomas\u00a0MC, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861\u20136.","journal-title":"Diabetes Care"},{"key":"2147_CR42","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.kint.2018.12.027","volume":"95","author":"T Banerjee","year":"2019","unstructured":"Banerjee\u00a0T, et\u00a0al. Poor accordance to a\u00a0DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension. Kidney Int. 2019;95:1433\u201342.","journal-title":"Kidney Int"},{"key":"2147_CR43","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.clnu.2019.10.004","volume":"39","author":"H Mozaffari","year":"2020","unstructured":"Mozaffari\u00a0H, Ajabshir\u00a0S, Alizadeh\u00a0S. Dietary approaches to stop hypertension and risk of chronic kidney disease: A systematic review and meta-analysis of observational studies. Clin Nutr. 2020;39:2035\u201344.","journal-title":"Clin Nutr"},{"key":"2147_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/ckj\/sfw046","volume":"9","author":"CC Tyson","year":"2016","unstructured":"Tyson\u00a0CC, et al. Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a\u00a0pilot feeding study. Clin Kidney\u00a0J. 2016;9:592\u20138.","journal-title":"Clin Kidney J"},{"key":"2147_CR45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/ndt\/gfx352","volume":"33","author":"E Yuzbashian","year":"2018","unstructured":"Yuzbashian\u00a0E, Asghari\u00a0G, Mirmiran\u00a0P, Amouzegar-Bahambari\u00a0P, Azizi\u00a0F. Adherence to low-sodium dietary approaches to stop hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: A\u00a0secondary prevention in prospective cohort study. Nephrol Dial Transplant. 2018;33:1159\u201368.","journal-title":"Nephrol Dial Transplant"},{"key":"2147_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.ajkd.2015.12.019","volume":"68","author":"D Dunkler","year":"2016","unstructured":"Dunkler\u00a0D, et al. Population-attributable fractions of modifiable lifestyle factors for CKD and mortality in individuals with type 2 diabetes: a cohort study. Am J Kidney Dis. 2016;68:29\u201340.","journal-title":"Am J Kidney Dis"},{"key":"2147_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41581-020-0323-4","volume":"16","author":"NG Docherty","year":"2020","unstructured":"Docherty\u00a0NG, le Roux\u00a0CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol. 2020;16:709\u201320.","journal-title":"Nat Rev Nephrol"},{"key":"2147_CR48","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.2337\/dc18-S007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S65\u2013S72.","journal-title":"Diabetes Care"},{"key":"2147_CR49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort\u00a0RT, et\u00a0al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"2147_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli\u00a0M, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a\u00a0population-level cohort study. Lancet. 2012;380:807\u201314.","journal-title":"Lancet"},{"key":"2147_CR51","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","volume":"64","author":"KR Tuttle","year":"2014","unstructured":"Tuttle\u00a0KR, et\u00a0al. Diabetic kidney disease: a\u00a0report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510\u201333.","journal-title":"Am J Kidney Dis"},{"key":"2147_CR52","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1681\/ASN.2012080870","volume":"24","author":"M Tonelli","year":"2013","unstructured":"Tonelli\u00a0M, et al. Association between LDL\u2011C and risk of myocardial infarction in CKD. J\u00a0Am Soc Nephrol. 2013;24:979\u201386.","journal-title":"J Am Soc Nephrol"},{"key":"2147_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro\u00a0CJ, et\u00a0al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727\u201349.","journal-title":"Nat Rev Nephrol"},{"key":"2147_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer\u00a0SC, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a\u00a0systematic review and meta-analysis. Ann Intern Med. 2012;157:263\u201375.","journal-title":"Ann Intern Med"},{"key":"2147_CR55","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","volume":"67","author":"X Su","year":"2016","unstructured":"Su\u00a0X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2147_CR56","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes\u00a0R, et\u00a0al. Effects of lowering LDL cholesterol on progression of kidney disease. J\u00a0Am Soc Nephrol. 2014;25:1825\u201333.","journal-title":"J Am Soc Nephrol"},{"key":"2147_CR57","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner\u00a0C, Tonelli\u00a0M, Kidney Disease. Improving global outcomes lipid guideline development work group, M. KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303\u20139.","journal-title":"Kidney Int"},{"issue":"6","key":"2147_CR58","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth\u00a0PP, et\u00a0al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397\u2013408.","journal-title":"Kidney Int"},{"key":"2147_CR59","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom\u00a0BC, et\u00a0al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N\u00a0Engl J Med. 2009;360:1395\u2013407.","journal-title":"N Engl J Med"},{"key":"2147_CR60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner\u00a0C, et\u00a0al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N\u00a0Engl J Med. 2005;353:238\u201348.","journal-title":"N Engl J Med"},{"key":"2147_CR61","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1097\/TP.0b013e3182861945","volume":"95","author":"C Margreiter","year":"2013","unstructured":"Margreiter\u00a0C, et al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type\u20112 diabetes mellitus. Transplantation. 2013;95:1030\u20136.","journal-title":"Transplantation"},{"key":"2147_CR62","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","volume":"371","author":"S Zoungas","year":"2014","unstructured":"Zoungas\u00a0S, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N\u00a0Engl J Med. 2014;371:1392\u2013406.","journal-title":"N Engl J Med"},{"key":"2147_CR63","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.ekir.2018.04.008","volume":"3","author":"FC Prischl","year":"2018","unstructured":"Prischl\u00a0FC, Wanner\u00a0C. Renal outcomes of antidiabetic treatment options for type 2 diabetes\u2014A proposed MARE definition. Kidney Int Rep. 2018;3:1030\u20138.","journal-title":"Kidney Int Rep"},{"key":"2147_CR64","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C, Inzucchi\u00a0SE, Zinman\u00a0B. Empagliflozin and progression of kidney disease in type 2 diabetes. N\u00a0Engl J Med. 2016;375:1801\u20132.","journal-title":"N Engl J Med"},{"key":"2147_CR65","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, et\u00a0al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"2147_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, et\u00a0al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2147_CR67","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, et\u00a0al. Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2147_CR68","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, et\u00a0al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N\u00a0Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2147_CR69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group, et al. Empagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"Engl J Med"},{"key":"2147_CR70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"2147_CR71","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N\u00a0Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2147_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et al. Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131\u20138.","journal-title":"Lancet"},{"key":"2147_CR73","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00108-012-3203-6","volume":"53","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner\u00a0G, Schernthaner\u00a0GH. Current treatment of type 2 diabetes. Internist (Berl). 2012;53:1399\u2013410.","journal-title":"Internist (Berl)"},{"key":"2147_CR74","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm4050948","volume":"4","author":"M Alsahli","year":"2015","unstructured":"Alsahli\u00a0M, Gerich\u00a0JE. Hypoglycemia in patients with diabetes and renal disease. J\u00a0Clin Med. 2015;4:948\u201364.","journal-title":"J Clin Med"},{"key":"2147_CR75","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","volume":"30","author":"AJ Scheen","year":"1996","unstructured":"Scheen\u00a0AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"2147_CR76","doi-asserted-by":"publisher","first-page":"c380","DOI":"10.1159\/000323739","volume":"118","author":"HJ Nye","year":"2011","unstructured":"Nye\u00a0HJ, Herrington\u00a0WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380\u2013c3.","journal-title":"Nephron Clin Pract"},{"key":"2147_CR77","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1440-1797.2010.01328.x","volume":"15","author":"HL Pilmore","year":"2010","unstructured":"Pilmore\u00a0HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton). 2010;15:412\u20138.","journal-title":"Nephrology (Carlton)"},{"key":"2147_CR78","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.2014.15298","volume":"312","author":"SE Inzucchi","year":"2014","unstructured":"Inzucchi\u00a0SE, Lipska\u00a0KJ, Mayo\u00a0H, Bailey\u00a0CJ, McGuire\u00a0DK. Metformin in patients with type 2 diabetes and kidney disease: a\u00a0systematic review. JAMA. 2014;312:2668\u201375.","journal-title":"JAMA"},{"key":"2147_CR79","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"JD Lalau","year":"2018","unstructured":"Lalau\u00a0JD, et\u00a0al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41:547\u201353.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"2147_CR80","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","volume":"30","author":"Guideline development group","year":"2015","unstructured":"Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR 45\u202fmL\/min). Nephrol Dial Transplant. 2015;30(Suppl 2):ii1\u2013142.","journal-title":"Nephrol Dial Transplant"},{"key":"2147_CR81","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","volume":"110","author":"SP Chan","year":"2015","unstructured":"Chan\u00a0SP, Colagiuri\u00a0S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110:75\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"2147_CR82","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1463-1326.2008.00928.x","volume":"10","author":"J Tayek","year":"2008","unstructured":"Tayek\u00a0J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10:1128\u20139. author reply 1129\u20131130.","journal-title":"Diabetes Obes Metab"},{"key":"2147_CR83","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","volume":"22","author":"BH Charbonnel","year":"2005","unstructured":"Charbonnel\u00a0BH, et al. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a\u00a0randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399\u2013405.","journal-title":"Diabet Med"},{"key":"2147_CR84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.27.1.141","volume":"27","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld\u00a0M, et al. One-year glycemic control with a\u00a0sulfonylurea plus pioglitazone versus a\u00a0sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141\u20137.","journal-title":"Diabetes Care"},{"key":"2147_CR85","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/dmrr.478","volume":"21","author":"DR Matthews","year":"2005","unstructured":"Matthews\u00a0DR, Charbonnel\u00a0BH, Hanefeld\u00a0M, Brunetti\u00a0P, Schernthaner\u00a0G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a\u00a0randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167\u201374.","journal-title":"Diabetes Metab Res Rev"},{"key":"2147_CR86","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1210\/jc.2003-030861","volume":"89","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner\u00a0G, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a\u00a0double-blind, randomized trial. J\u00a0Clin Endocrinol Metab. 2004;89:6068\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"2147_CR87","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2337\/dci17-0026","volume":"40","author":"IH de Boer","year":"2017","unstructured":"de Boer\u00a0IH, et\u00a0al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273\u201384.","journal-title":"Diabetes Care"},{"key":"2147_CR88","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00508-019-01565-0","volume":"131","author":"T Weber","year":"2019","unstructured":"Weber\u00a0T, et\u00a0al. Austrian consensus on high blood pressure 2019. Wien Klin Wochenschr. 2019;131:489\u2013590.","journal-title":"Wien Klin Wochenschr"},{"key":"2147_CR89","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","volume":"62","author":"SJ Taler","year":"2013","unstructured":"Taler\u00a0SJ, et\u00a0al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201\u201313.","journal-title":"Am J Kidney Dis"},{"key":"2147_CR90","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli\u00a0FH, et\u00a0al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884\u201393.","journal-title":"Ann Intern Med"},{"key":"2147_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archinternmed.2011.619","volume":"172","author":"CA Peralta","year":"2012","unstructured":"Peralta\u00a0CA, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172:41\u20137.","journal-title":"Arch Intern Med"},{"key":"2147_CR92","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/0003-4819-159-4-201308200-00004","volume":"159","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy\u00a0CP, et\u00a0al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a\u00a0cohort study. Ann Intern Med. 2013;159:233\u201342.","journal-title":"Ann Intern Med"},{"key":"2147_CR93","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis\u00a0EJ, Hunsicker\u00a0LG, Bain\u00a0RP, Rohde\u00a0RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N\u00a0Engl J Med. 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"2147_CR94","doi-asserted-by":"publisher","first-page":"i438","DOI":"10.1136\/bmj.i438","volume":"352","author":"S Bangalore","year":"2016","unstructured":"Bangalore\u00a0S, Fakheri\u00a0R, Toklu\u00a0B, Messerli\u00a0FH. Diabetes mellitus as a\u00a0compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.","journal-title":"BMJ"},{"key":"2147_CR95","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried\u00a0LF, et\u00a0al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N\u00a0Engl J Med. 2013;369:1892\u2013903.","journal-title":"N Engl J Med"},{"key":"2147_CR96","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving\u00a0HH, et\u00a0al. Cardiorenal end points in a\u00a0trial of aliskiren for type 2 diabetes. N\u00a0Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"2147_CR97","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann\u00a0JF, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a\u00a0multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547\u201353.","journal-title":"Lancet"},{"key":"2147_CR98","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, et\u00a0al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2147_CR99","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, et\u00a0al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N\u00a0Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2147_CR100","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, et\u00a0al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart\u00a0J. 2022;43:474\u201384.","journal-title":"Eur Heart J"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-022-02147-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:08:25Z","timestamp":1682550505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-022-02147-3"}},"subtitle":["Positionspapier der \u00d6sterreichischen Diabetes Gesellschaft und der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie","Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":100,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1007\/s00508-022-02147-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"21 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Sourij hat von folgenden Unternehmen, die auch tlw. f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amarin, Amgen, AstraZeneca, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, Eli Lilly, Kapsch, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis. R.\u00a0Edlinger hat von folgenden Unternehmen Kongre\u00dfunterst\u00fctzung, Honorar f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amgen, Astellas, AstraZeneca, Boehringer-Ingelheim, Fresenius-Kabi, Novartis, Sanofi-Aventis, Vifor. F.C.\u00a0Prischl hat von folgenden Unternehmen Reiseunterst\u00fctzungen oder Honorar f\u00fcr Vortr\u00e4ge oder Advisory Boards erhalten: Amgen, Astellas, AstraZeneca, Boehringer-Ingelheim, Bayer Pharma, Eli Lilly, Fresenius Medical Care, Gambro, Janssen-Cilag Pharma, Novartis, ratiopharm, Roche, Takeda Pharma, Wyeth-Lederle. S.\u00a0Kaser hat von folgenden Unternehmen, die zT auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amarin, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Viatris. S.\u00a0Horn hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Astra Zeneca, Amgen, Bayer Pharma, Boehringer Ingelheim, Daiichi Sankyo, Fresenius, GlaxoSmithKline, Janssen Cilag, Novartis, Novo Nordisk, Otsuka, Pfizer, Vifor. M.\u00a0Antlanger hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Astra Zeneca, Amgen, Baxter, Boehringer Ingelheim, GlaxoSmithKline, Janssen Cilag, Novartis, Vifor. B.\u00a0Paulweber hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Merck Sharp Dohme, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis. F.\u00a0Aberer hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: Amgen, Sanofi, Novo Nordisk, Astra Zeneca und Boehringer Ingelheim. H.\u00a0Stingl hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit, bzw. Fortbildungsunterst\u00fctzung im Rahmen der (dienst)rechtlichen Rahmenbedingungen (Einladung zu Kongressen) erhalten: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Menarini, MSD, Mylan, Novo Nordisk, Novartis, Sanofi Aventis, Servier. Zus\u00e4tzlich gibt H.\u00a0Stingl an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit erhalten: Astra Zeneca, B\u00f6hringer-Ingelheim, Novo Nordisk, Lilly, Amgen, Novartis. S.\u00a0Schmaldienst hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit erhalten: AstraZeneca und B\u00f6hringer-Ingelheim. M.\u00a0S\u00e4emann hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit und Studienunterst\u00fctzung erhalten: Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis, and Otsuka. M.\u00a0Clodi hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit erhalten:Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, Novo Nordisk, Daiichi, Amgen, Abbott, Dexcom, Medtrust. G.\u00a0Mayer hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und Forschungsunterst\u00fctzung erhalten: AstraZeneca, B\u00f6hringer Ingelheim und NovoNordisk. R.\u00a0Oberbauer, hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit und Studienunterst\u00fctzung erhalten: AstraZeneca, B\u00f6hringer Ingelheim, Eli Lilly, Astellas. J.\u00a0Brix, D.\u00a0Cejka, und A.\u00a0Rosenkranz geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}